VIVUS, Inc. (VVUS) Obesity Drug Gets Expected European Rejection
10/19/2012 8:02:26 AM
VIVUS, Inc. | Jobs at VIVUS, Inc.
Vivus Inc.'s obesity drug, approved in July in the U.S., failed to gain the backing of European drug regulators because of its potential side effects.
The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended against approving Vivus’s pill, to be marketed under the name Qsiva in Europe, because of concerns about negative cardiovascular and nervous system effects from long-term use, the Mountain View, California-based company said yesterday in a statement. Vivus plans to appeal the decision.
comments powered by